Celera initially announced that it would seek patent protection on "only 200–300" genes, but later amended this to seeking "intellectual property protection" on "fully-characterized important structures" amounting to 100–300 targets.
塞雷拉基因組一开始宣称只寻求对200至300个基因的专利权保护，但随后又修改为寻求对“完全鉴定的重要结构”的总共100至300个靶基因进行知识产权保护。